Collaboration and License Agreements - Narrative (Details)						1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 16, 2021 USD ($)	May 26, 2021 USD ($)	Dec. 26, 2020 USD ($)	Mar. 31, 2020 USD ($)	Mar. 30, 2020 USD ($)	Dec. 31, 2020 USD ($) milestone	Apr. 30, 2020 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 31, 2021 USD ($)	Mar. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additions										$ 0
Cost share advance								$ 84,768,000		84,768,000					$ 121,862,000
Amounts due to Pfizer								19,957,000		19,957,000					1,954,000
Deferred revenue										28,652,000	$ (23,333,000)
Pfizer collaboration revenue								$ 25,172,000	$ 0	54,681,000	0
Cost share advance from Pfizer										(38,304,000)	0
Shared costs										$ 38,304,000
Richter
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License Agreement, Regulatory Milestones, Upfront Payment Received				$ 40,000,000
Maximum payment from regulatory milestones achieved					$ 40,000,000
Regulatory milestone payments received	$ 15,000,000				25,000,000
Maximum payment from sales-related milestones achieved					107,500,000
Remaining transaction price					$ 50,000,000
Additions to deferred revenue							$ 10,000,000
Percentage of performance obligation satisfied								66.66%		66.66%
Richter | Revenue Recognized Upon Completion of Delivery
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues								$ 16,700,000			$ 33,300,000
Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum payment from regulatory milestones achieved			$ 100,000,000											$ 100,000,000
Maximum payment from sales-related milestones achieved			$ 3,500,000,000
Additions to deferred revenue		$ 100,000,000
Percentage of revenue recognized			100.00%
Upfront payment received						$ 650,000,000
Maximum payment from milestones achieved			$ 3,700,000,000
Number of regulatory milestones | milestone						2
Maximum aggregate payment from milestones achieved			200,000,000
Additions			$ 150,000,000
Repayment period			2 years
Reduction in cost share advance from implied financing costs			$ 3,600,000
Deferred revenue, recognition period			6 years
Amounts due to Pfizer								20,000,000		$ 20,000,000					1,900,000
Amounts due to collaboration partner, share of profits								$ 8,600,000		$ 8,600,000					$ 1,800,000
Percentage of revenue recognized by counterparty								50.00%		50.00%					50.00%
Amounts due to collaboration partner, reimbursement of allowable expenses								$ 11,400,000		$ 11,400,000					$ 100,000
Pfizer collaboration revenue										54,700,000
Cost share advance from Pfizer										$ 37,100,000
Percentage of reimbursement of Allowable Expenses										50.00%
Shared costs										$ 38,300,000
Accretion of implied financing costs										1,200,000
Pfizer | R&D expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shared costs										13,900,000
Pfizer | SG&A expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shared costs										$ 24,400,000
Pfizer | Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Costs covered by company												$ 50,000,000	$ 100,000,000